The Pipeline Flows East

Something has shifted in how the world’s largest drug companies fill their pipelines, and it happened faster than almost anyone predicted. By 2024, roughly a third of the innovative, in-licensed assets in Big Pharma’s pipeline originated in China, molecules discovered in Chinese labs and licensed to Western firms to develop and sell.^[2] The direction of the drug trade, once firmly West-to-East, has begun to reverse.

The numbers rose steeply. China-to-West licensing reached about $8.4 billion across 48 deals in 2024, double the private capital Chinese biotech raised that year, and by 2025 the annual out-licensing total had climbed to a reported record.^[2] Over one sixteen-month stretch, six of the twenty-six largest global pharma deals involved a Chinese biotech, worth roughly $53 billion between them.^[4]

The molecules are Chinese; the marketing is Western. Big Pharma has become, in part, a distribution channel for Chinese science.

The marquee cheques

The headline deals are large. In May 2025 Pfizer licensed a PD-1/VEGF bispecific antibody from 3SBio for $1.25 billion upfront, up to $4.8 billion in milestones and a $100 million equity stake.^[1] Earlier, Summit paid Akeso $500 million upfront for the drug, ivonescimab, that touched off the whole PD-1×VEGF gold rush. And a new structure has emerged: the “NewCo,” in which Western venture investors build a company around a Chinese-licensed asset, as when Hengrui’s obesity drugs seeded a firm that raised a $400 million launch round.^[3]

Two honest caveats. Headline deal values are “biobucks” — upfront cash plus milestones rarely paid in full; the load-bearing number is the upfront (3SBio’s $1.25 billion, Summit’s $500 million). And the largest annual totals come from trade databases whose methods differ, so treat the record figure as an estimate, not a constant.

How this reaches a portfolio

This is the single most important structural change in global biopharma, and it reframes where drug value is created. China has become a discovery engine whose output the West increasingly rents, which turns the out-licensing deal itself into the key instrument to watch, upfronts as the real price signal, the therapeutic classes where China leads (bispecifics, ADCs, cell therapies), and the NewCo as a repeatable vehicle. The reflex to treat Chinese biotech as a follower is already out of date at the dealmaking layer; the interesting question is no longer whether the pipeline flows east, but how much further it goes.